Cardiopulmonary bypass in malignant hyperthermia susceptible patients: A systematic review of published cases

被引:14
|
作者
Metterlein, Thomas [1 ]
Zink, Wolfgang [1 ]
Kranke, Eva [3 ]
Haneya, Assad [2 ]
Graf, Bernhard [1 ]
Kranke, Peter [4 ]
机构
[1] Univ Hosp Regensburg, Dept Anesthesiol, D-93051 Regensburg, Germany
[2] Univ Hosp Regensburg, Dept Cardiosurg, D-93051 Regensburg, Germany
[3] Univ Hosp Wurzburg, Dept Cardiosurg, Wurzburg, Germany
[4] Univ Hosp Wurzburg, Dept Anesthesia & Crit Care, Wurzburg, Germany
来源
关键词
CORONARY-ARTERY-BYPASS; SKELETAL-MUSCLE PREPARATIONS; MITRAL-VALVE-REPLACEMENT; CENTRAL CORE DISEASE; CARDIAC-SURGERY; DANTROLENE; RHABDOMYOLYSIS; DIAGNOSIS; MANAGEMENT; SWINE;
D O I
10.1016/j.jtcvs.2011.01.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Malignant hyperthermia susceptibility is an important risk factor during general anesthesia. Affected patients have an asymptomatic but potentially lethal hypermetabolic reaction after contact with volatile anesthetics or succinylcholine. Classic symptoms include hemodynamic instability, combined with acidosis, rigor, and hyperthermia. During cardiopulmonary bypass, these signs may be obscured, delaying correct diagnosis and lifesaving treatment. Malignant hyperthermia-susceptible individuals are more sensitive to heat and stress, so rewarming and catecholamine administration may trigger an episode, necessitating prophylactic measures. Methods: This systematic review identified typical malignant hyperthermia symptoms during cardiopulmonary bypass and investigated other factors in cardiac surgery that might trigger an episode in susceptible individuals. Approaches used to treat and prevent malignant hyperthermia during cardiopulmonary bypass were systematically analyzed. We conducted a systematic search for reports about malignant hyperthermia and cardiopulmonary bypass. Search terms included malignant hyperthermia and cardiopulmonary bypass, extracorporeal circulation, or cardiac surgery. Results: We found 24 case reports and case series including details of 26 patients. In 14 cases, malignant hyperthermia crises during or shortly after cardiopulmonary bypass were described. Fourteen reports discussed prevention of an episode. Early symptoms of a malignant hyperthermia episode include excessive carbon dioxide production and metabolic acidosis. Massively increased creatine kinase levels are a strong indicator of a malignant hyperthermia reaction. Rewarming is associated with development of clinical signs of malignant hyperthermia. Conclusions: In potentially susceptible patients, apart from avoiding classic trigger substances, aggressive rewarming should not be applied. Hemodynamic instability in conjunction with the described symptoms should result in a diagnostic algorithm. (J Thorac Cardiovasc Surg 2011;141:1488-95)
引用
收藏
页码:1488 / 1495
页数:8
相关论文
共 50 条
  • [31] Sevoflurane-induced malignant hyperthermia during cardiopulmonary bypass and moderate hypothermia
    Jonassen, AA
    Petersen, AJ
    Mohr, S
    Andersson, C
    Skattum, J
    Kvernebo, K
    Paulsen, OG
    Stokland, O
    Kirkeboen, KA
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2004, 48 (08) : 1062 - 1065
  • [32] The European Malignant Hyperthermia Group consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients
    Heiderich, Sebastian
    Bastian, Borge
    Johannsen, Stephan
    Klingler, Werner
    Ruffert, Henrik
    Schuster, Frank
    ANAESTHESIST, 2021, 70 (02): : 155 - 157
  • [33] PROPOFOL IS A SAFE ANESTHETIC AGENT IN MALIGNANT HYPERTHERMIA SUSCEPTIBLE PATIENTS
    MCKENZIE, AJ
    COUCHMAN, KG
    POLLOCK, N
    ANAESTHESIA AND INTENSIVE CARE, 1992, 20 (02) : 165 - 168
  • [34] Using Informatics to Improve the Care of Patients Susceptible to Malignant Hyperthermia
    Denholm, Bonnie G.
    AORN JOURNAL, 2016, 103 (04) : 364 - 376
  • [35] MANAGEMENT OF OTOLARYNGIC PATIENTS SUSCEPTIBLE TO MALIGNANT HYPERTHERMIA WITHOUT DANTROLENE
    DERKAY, CS
    GRUNDFAST, KM
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1991, 105 (05) : 680 - 686
  • [36] Management of patients susceptible to malignant hyperthermia: A surgeon?s perspective
    Carlson, Kevin J.
    Sun, Sara A.
    Swan, Carol
    Koenig, Matthias
    Derkay, Craig S.
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2022, 159
  • [37] In-vitro effects of cocaine in malignant hyperthermia susceptible patients
    Weisshorn, R
    Wappler, F
    Scholz, J
    Fiege, M
    Esch, JSA
    ANESTHESIOLOGY, 1999, 91 (3A) : U216 - U216
  • [38] Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients
    Pollock, N
    Langton, E
    Stowell, K
    Simpson, C
    McDonnell, N
    ANAESTHESIA AND INTENSIVE CARE, 2004, 32 (04) : 502 - 509
  • [39] Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group
    Rueffert, Henrik
    Bastian, Boerge
    Bendixen, Diana
    Girard, Thierry
    Heiderich, Sebastian
    Hellblom, Anna
    Hopkins, Philip M.
    Johannsen, Stephan
    Snoeck, Marc M.
    Urwyler, Albert
    Glahn, Klaus P. E.
    BRITISH JOURNAL OF ANAESTHESIA, 2021, 126 (01) : 120 - 130
  • [40] Lactic acidosis in HIV infected patients: a systematic review of published cases
    Arenas-Pinto, A
    Grant, AD
    Edwards, S
    Weller, IVD
    SEXUALLY TRANSMITTED INFECTIONS, 2003, 79 (04) : 340 - 344